The U.S. Food and Drug Administration has approved a new drug to treat complicated urinary tract infections (cUTI). The antibacterial drug, created by Rempex Pharmaceuticals, can also treat pyelonephritis, a kidney infection caused by specific bacteria.
“The FDA is committed to making new safe and effective antibacterial drugs available,” said Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, in a press release. “This approval provides an additional treatment for patients with cUTI, a type of serious bacterial infection.”
Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria. It should only be used to treat infections proven or strongly suspected to be caused by susceptible bacteria.
The most common adverse drug reactions were headache, infusion site reactions and diarrhea. Vabomere is associated with serious risks, including allergic reactions and seizures, and should not be taken by people with a history of anaphylaxis.